Home » Misleading Treanda Statements Draw Untitled Letter
Misleading Treanda Statements Draw Untitled Letter
A pocket dosing card for Cephalon’s cancer
drug Treanda omits important risk information, according to an FDA untitled letter.
The card warns physicians of the possibility of patients developing infections but does not provide any further information, such as the fact that infection
has been associated with hospitalization, septic shock and death, the Division of Drug Marketing, Advertising and Communications letter says.
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May